Study of Cord Blood Transplantation as Treatment for Children and Young Adults With Blood Cancers

What this Trial Is About

Researchers are evaluating cord blood transplantation CBT as a treatment for children and young adults up to 26 years old with various blood cancers, including acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and lymphomas. The study focuses on whether CBT used as a first or second transplant can be effective, especially for those who lack matched donors within a short time frame. Participants include those in remission or with relapsedrefractory disease, and the study is sponsored by Memorial Sloan Kettering Cancer Center. The study involves two groups one with high-risk disease and no prior transplant, and another with very high-risk disease including patients who had a prior transplant or relapsed disease. Treatments include minimally manipulated unrelated cord blood units along with preparative therapies such as total body irradiation, chemotherapy drugs like cyclophosphamide, fludarabine, clofarabine, busulfan, thiotepa, and immunosuppressants including tacrolimus, mycophenolate mofetil, and cyclosporine. The second transplant is scheduled at least four months after the first when applicable. Participants will undergo regular evaluations including bone marrow tests for disease status, organ function assessments, and monitoring of immune response and side effects. The main outcome measured is disease-free survival one year after transplantation. The study requires adherence to treatment protocols, long-term follow-up, and safety monitoring, lasting until at least April 2030. Participants will have various clinical and laboratory assessments throughout the study to monitor health and treatment effects.

Cord Blood Transplantation in Children and Young Adults With Blood Cancer